Drugs / KK-LC-1 TCR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05035407 | Mar 2022 → Jul 2025 | — | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KK-LC-1 TCR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05035407 ↗ |
| Modality | Cell therapy | “TCR T cell therapy targeting CG antigens” NCT05035407 ↗ |
| Route | Other | “given back to the participant through an injection into the participant's tumor” NCT05035407 ↗ |